TheraCryf plc (AIM: TCF), a clinical-stage drug development company focused on neuropsychiatry and oncology, announced on Monday that it has entered into a Master Service Agreement with Pharmaron UK Ltd (SZ: 300759 / HK: 3759.HK) to advance its Orexin-1 (Ox-1) addiction programme.

Pharmaron will deliver preclinical services required to support clinical trial authorisation applications, including manufacturing scale-up, formulation, clinical supply, and regulatory-standard toxicology. Work is expected to begin shortly, with study completions anticipated in the second half of 2026.

The Ox-1 programme is a key initiative for TheraCryf, supported by recent fundraising. The company aims to generate proof-of-concept data to attract pharma partners for later-stage development and commercialisation.

TheraCryf operates a diversified pipeline targeting addiction, anxiety, fatigue, narcolepsy, glioblastoma and neurodevelopmental disorders. It maintains collaborations with leading academic institutions and industry partners including Stalicla SA, and has sourced programme know-how from Shire (now Takeda).